Lung Cancer | Specialty

Efficacy and Safety of Afatinib vs Erlotinib and Gefitinib in EGFR+ NSCLC

December 17th 2016

Options for Up-front Therapy in EGFR-mutant NSCLC

December 17th 2016

Mutation Testing for NSCLC in 2017

December 17th 2016

Dr. Mutti on Predicting Response to Immunotherapy for Mesothelioma

December 15th 2016

Luciano Mutti, MD, professor in Cancer Research, University of Salford Manchester, discusses predicting clinical response to immunotherapy agents for patients with mesothelioma.

Adequate Testing Critical to Advancing Care in NSCLC Patients With Rare Mutations

December 15th 2016

Though testing for mutations in EGFR, ALK, and ROS1 is a standard approach in patients with non–small cell lung cancer, the same is not true for less common genetic abnormalities, including RET, BRAF, c-MET, and NTRK.

Researchers Aim to Refine Use of VEGF, EGFR Inhibitors in NSCLC

December 15th 2016

Researchers are exploring VEGF and EGFR inhibitors in combination with other therapies for patients with non–small cell lung cancer in hopes of maximizing clinical outcomes while keeping toxicity levels low.

Nivolumab Shows Promise in Mesothelioma

December 14th 2016

Treatment with the PD-1 inhibitor nivolumab showed promising results in patients with recurrent malignant pleural mesothelioma.

Expert Explains Keys to Additional Advances in Lung Cancer

December 12th 2016

The field of lung cancer has undoubtedly seen notable advances over the past year—especially with the game-changing November 2016 approval of pembrolizumab for the frontline treatment of patients with non–small cell lung cancer.

Combinations, Better Biomarkers Key to Advancing Immunotherapy in NSCLC

December 12th 2016

Beyond the strong efficacy outcomes observed with single-agent immunotherapies in non–small cell lung cancer—including pembrolizumab, nivolumab, and atezolizumab—the field is now awaiting the next phase: combination regimens.

Tepotinib Takes Aim at Novel MET Mutation in Lung Cancer Trial

December 12th 2016

Tepotinib, an investigational small molecule that targets a recently identified aberration in the MET gene, is moving forward rapidly in clinical development for patients with non–small cell lung cancer who harbor the mutation, raising hopes that a more specific attack on the signaling pathway will lead to a new therapy for a significant subgroup of individuals with the disease.

First Steps Taken Toward Harmonization of PD-L1 Immunohistochemistry Testing in France

December 8th 2016

Determination of the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.

Durvalumab Provides Durable Response in Heavily Pretreated Metastatic NSCLC

December 8th 2016

Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.

Atezolizumab Improves Survival in Second-Line NSCLC

December 8th 2016

Treatment with the PD-L1 inhibitor atezolizumab significantly improved overall survival compared to standard chemotherapy in patients with non–small lung cancer who progressed on platinum-based chemotherapy.

Frontline Pembrolizumab Shows Superior Health-Related QoL in NSCLC

December 7th 2016

Patients with non–small cell lung cancer treated in the pembrolizumab arm of the KEYNOTE-024 trial experienced improved quality of life compared with patients who were treated with standard chemotherapy.

Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

December 7th 2016

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC

December 7th 2016

Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Osimertinib Beats Chemo in Second-Line T790M-Mutant NSCLC

December 7th 2016

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.

Frontline Ceritinib Improves PFS Over Platinum-Based Chemo in ALK+ NSCLC

December 7th 2016

Frontline treatment with ceritinib (Zykadia) improved progression-free survival over standard chemotherapy in patients with ALK-rearranged non–small cell lung cancer.

Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC

December 6th 2016

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Verschraegen on the JAVELIN Solid Tumor Trial in Advanced NSCLC

December 6th 2016

Claire Verschraegen, MD, professor of Medical Oncology, University of Vermont Cancer Center, discusses the results of the JAVELIN Solid Tumor trial during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.